Integrating mutation data and structural analysis of the TP53 tumor, suppressor protein

被引:109
作者
Martin, ACR
Facchiano, AM
Cuff, AL
Hernandez-Boussard, T
Olivier, M
Hainaut, P
Thornton, JM
机构
[1] Univ Reading, Sch Anim & Microbial Sci, Reading RG6 6AJ, Berks, England
[2] Univ Naples 2, CRISCEB Res Ctr Computat & Biotechnol Sci, Naples, Italy
[3] Int Agcy Res Canc, F-69372 Lyon, France
[4] UCL, Dept Biochem & Mol Biol, Biomol Struct & Modelling Unit, London, England
[5] Univ London Birkbeck Coll, Dept Crystallog, London WC1E 7HX, England
关键词
p53; TP53; relational database; structural analysis; SNP; DNA binding; transcription factor; tumor suppressor;
D O I
10.1002/humu.10032
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
TP53 encodes p53, which is a nuclear phosphoprotein with cancer,inhibiting properties. In response to DNA damage, p53 is activated and mediates a set of antiproliferative responses including cell,cycle arrest and apoptosis. Mutations in the TP53 gene are associated with more than 50% of human cancers, and 90% of these affect p53-DNA interactions, resulting in a partial or complete loss of transactivation functions. These mutations affect the structural integrity and/or p53 DNA interactions, leading to the partial or complete loss of the protein's function. We report here the results of a systematic automated analysis of the effects of p53 mutations on the structure of the core domain of the protein. We found that 304 of the 882 (34.4%) distinct mutations reported in the core domain can be explained in structural terms by their predicted effects on protein folding or on protein-DNA contacts. The proportion of "explained" mutations increased to 55.6% when substitutions of evolutionary conserved amino acids were included. The automated method of structural analysis developed here may be applied to other frequently mutated gene mutations such as dystrophin, BRCA1, and G6PD. Hum Mutat 19:149-164, 2002. (C) 2002 Wiley-Liss, Inc.
引用
收藏
页码:149 / 164
页数:16
相关论文
共 58 条
  • [1] Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients
    Aas, T
    Borresen, AL
    Geisler, S
    SmithSorensen, B
    Johnsen, H
    Varhaug, JE
    Akslen, LA
    Lonning, PE
    [J]. NATURE MEDICINE, 1996, 2 (07) : 811 - 814
  • [2] CODON-72 POLYMORPHISM OF THE TP53 GENE
    ARA, S
    LEE, PSY
    HANSEN, MF
    SAYA, H
    [J]. NUCLEIC ACIDS RESEARCH, 1990, 18 (16) : 4961 - 4961
  • [3] HYDROGEN-BONDING IN GLOBULAR-PROTEINS
    BAKER, EN
    HUBBARD, RE
    [J]. PROGRESS IN BIOPHYSICS & MOLECULAR BIOLOGY, 1984, 44 (02) : 97 - 179
  • [4] Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations
    Brachmann, RK
    Yu, KX
    Eby, Y
    Pavletich, NP
    Boeke, JD
    [J]. EMBO JOURNAL, 1998, 17 (07) : 1847 - 1859
  • [5] A ROLE FOR SUNLIGHT IN SKIN-CANCER - UV-INDUCED P53 MUTATIONS IN SQUAMOUS-CELL CARCINOMA
    BRASH, DE
    RUDOLPH, JA
    SIMON, JA
    LIN, A
    MCKENNA, GJ
    BADEN, HP
    HALPERIN, AJ
    PONTEN, J
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (22) : 10124 - 10128
  • [6] p53 transcriptional activity is essential for p53-dependent apoptosis following DNA damage
    Chao, C
    Saito, S
    Kang, J
    Anderson, CW
    Appella, E
    Xu, Y
    [J]. EMBO JOURNAL, 2000, 19 (18) : 4967 - 4975
  • [7] CHIBA I, 1990, ONCOGENE, V5, P1603
  • [8] CRYSTAL-STRUCTURE OF A P53 TUMOR-SUPPRESSOR DNA COMPLEX - UNDERSTANDING TUMORIGENIC MUTATIONS
    CHO, YJ
    GORINA, S
    JEFFREY, PD
    PAVLETICH, NP
    [J]. SCIENCE, 1994, 265 (5170) : 346 - 355
  • [9] REFINED SOLUTION STRUCTURE OF THE OLIGOMERIZATION DOMAIN OF THE TUMOR-SUPPRESSOR P53
    CLORE, GM
    ERNST, J
    CLUBB, R
    OMICHINSKI, JG
    KENNEDY, WMP
    SAKAGUCHI, K
    APPELLA, E
    GRONENBORN, AM
    [J]. NATURE STRUCTURAL BIOLOGY, 1995, 2 (04): : 321 - 333
  • [10] CRAWFORD L, 1983, INT REV EXP PATHOL, V25, P1